Comparable efficacy and safety of COVID-19 vaccines for patients receiving tegafur–uracil as postoperative adjuvant chemotherapy

1. Pollard CA, Morran MP, Nestor-Kalinoski AL. The COVID19 pandemic: a global health crisis. Physiol Genomics.

2020;52(11):549–57.

13

2. Vabret N, Britton GJ, Gruber C, Hegde S, Kim J, Kuksin M,

et al. Immunology of COVID-19: current state of the science.

Immunity. 2020;52(6):910–41.

3. Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, et al. Patients

with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak. Cancer Discov.

2020;10(6):783–91.

4. Luo J, Rizvi H, Preeshagul IR, Egger JV, Hoyos D, Bandlamudi

C, et al. COVID-19 in patients with lung cancer. Ann Oncol.

2020;31(10):1386–96.

5. World Health Organization. COVID-19 Vaccines WHO EUL

Issued. https://​extra​net.​who.​int/​pqweb/​vacci​nes/​vacci​nesco​vid-​

19-​vacci​ne-​eul-​issued. Accessed 6 Feb 2022.

6. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A,

Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA

COVID-19 vaccine. N Engl J Med. 2020;383(27):2603–15.

7. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak

R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2

vaccine. N Engl J Med. 2021;384(5):403–16.

8. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM,

Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19

vaccine (AZD1222) against SARS-CoV-2: an interim analysis

of four randomised controlled trials in Brazil, South Africa, and

the UK. Lancet. 2021;397(1–269):99–111.

9. Herishanu Y, Avivi I, Aharon A, Shefer G, Levi S, Bronstein

Y, et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood.

2021;137(23):3165–73.

10. Massarweh A, Eliakim-Raz N, Stemmer A, Levy-Barda A,

Yust-Katz S, Zer A, et al. Evaluation of seropositivity following BNT162b2 messenger RNA vaccination for SARS-CoV-2

in patients undergoing treatment for cancer. JAMA Oncol.

2021;7(8):1133–40.

11. Kato H, Ichinose Y, Ohta M, Hata E, Tsubota N, Tada H,

et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med.

2004;350(17):1713–21.

12. Shrotri M, Navaratnam AMD, Nguyen V, Byrne T, Geismar C,

Fragaszy E, et al. Spike-antibody waning after second dose of

BNT162b2 or ChAdOx1. Lancet. 2021;398(10298):385–7.

13. Levin EG, Lustig Y, Cohen C, Fluss R, Indenbaum V, Amit S,

et al. Waning immune humoral response to BNT162b2 COVID19 vaccine over 6 months. N Engl J Med. 2021;385(24): e84.

14. Earle KA, Ambrosino DM, Fiore-Gartland A, Goldblatt

D, Gilbert PB, Siber GR, et al. Evidence for antibody as

a protective correlate for COVID-19 vaccines. Vaccine.

2021;39(32):4423–8.

15. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK,

Juno JA, et al. Neutralizing antibody levels are highly predictive

of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27(7):1205–11.

16. Wheeler SE, Shurin GV, Yost M, Anderson A, Pinto L, Wells

A, et al. Differential antibody response to mRNA COVID19 vaccines in healthy subjects. Microbiol Spectr. 2021;9(1):

e0034121.

17. Funakoshi Y, Yakushijin K, Ohji G, Hojo W, Sakai H, Takai

R, et al. Safety and immunogenicity of the COVID-19 vaccine

BNT162b2 in patients undergoing chemotherapy for solid cancer. J Infect Chemother. 2021. https://​doi.​org/​10.​1016/j.​jiac.​

2021.​12.​021.

18. Haberman RH, Herati R, Simon D, Samanovic M, Blank

RB, Tuen M, et al. Methotrexate hampers immunogenicity to

BNT162b2 mRNA COVID-19 vaccine in immune-mediated

inflammatory disease. Ann Rheum Dis. 2021;80(10):1339–44.

19. Mahil SK, Bechman K, Raharja A, Domingo-Vila C, Baudry

D, Brown MA, et al. Humoral and cellular immunogenicity to a

Surgery Today second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal

cohort study. Lancet Rheumatol. 2022;4(1):e42–52.

20. Sadarangani M, Marchant A, Kollmann TR. Immunological

mechanisms of vaccine-induced protection against COVID-19

in humans. Nat Rev Immunol. 2021;21(8):475–84.

2 1. Miceli R, Calabretta L, Verderio P, Ljevar S, Serpenti F, Morelli

D, et al. T-cell immune response after mRNA SARS-CoV-2

vaccines is frequently detected also in the absence of seroconversion in patients with lymphoid malignancies. Br J Haematol.

2022;196(3):548–58.

22. Prendecki M, Clarke C, Edwards H, McIntyre S, Mortimer

P, Gleeson S, et al. Humoral and T-cell responses to SARSCoV-2 vaccination in patients receiving immunosuppression.

Ann Rheum Dis. 2021;80(10):1322–9.

Publisher's Note Springer Nature remains neutral with regard to

jurisdictional claims in published maps and institutional affiliations.

13

...